This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andersson, T. L. Articles by Vinge, E. Search for Related Content PubMed PubMed Citation Articles by Andersson, T. L. Articles by Vinge, E.

Circulation, Vol 81, 872-878, Copyright © 1990 by American Heart Association

ARTICLES

Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation

TL Andersson, JO Solem, L Tengborn and E Vinge
Department of Clinical Pharmacology, University Hospital, Lund, Sweden.

The effects of desmopressin acetate (DDAVP) on platelet aggregation and the von Willebrand factor antigen (vWF:Ag) were studied in 19 patients undergoing cardiac surgery with extracorporeal circulation. The patients represented one of five blocks in a randomized double-blind placebo-controlled parallel group trial on the effects of DDAVP on postoperative bleeding after uncomplicated coronary artery bypass operations. After termination of extra-corporeal circulation, DDAVP (0.3 microgram/kg body wt) or its vehicle was infused into a peripheral vein throughout 15 minutes. The increase in factor VIII coagulant activity after infusion did not differ between the groups but there was a significantly larger increase in vWF:Ag levels in DDAVP-treated patients. The aggregatory response to adenosine-diphosphate (ADP) and ristocetin showed a normal pattern and was not significantly different between the two groups. As compared with placebo, DDAVP did not decrease the bleeding time or the postoperative blood loss. We conclude that DDAVP causes an increase in vWF:Ag levels but does not alter platelet aggregation, bleeding time, or blood loss in uncomplicated coronary artery bypass patients.

This article has been cited by other articles:

				E. Ozal, E. Kuralay, H. Bingol, F. Cingoz, S. Ceylan, and H. Tatar Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis? J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 539 - 543. [Abstract] [Full Text] [PDF]

				W. C. Oliver Jr, P. J. Santrach, G. K. Danielson, G. A. Nuttall, D. R. Schroeder, and M. H. Ereth Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations Ann. Thorac. Surg., December 1, 2000; 70(6): 1923 - 1930. [Abstract] [Full Text] [PDF]

				P. M. Mannucci Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years Blood, October 1, 1997; 90(7): 2515 - 2521. [Full Text] [PDF]

				D. Royston Systemic inflammatory responses to surgery with cardiopulmonary bypass Perfusion, May 1, 1996; 11(3): 177 - 189. [PDF]

				E. W. Salzman, M. J. Weinstein, D. Reilly, and J. A. Ware Adventures in Hemostasis: Desmopressin in Cardiac Surgery Arch Surg, February 1, 1993; 128(2): 212 - 217. [Abstract] [PDF]